Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
This article was originally published in The Tan Sheet
Executive Summary
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants
You may also be interested in...
FDA Guidance Raises Prospect Of More INDs For Supplement Research
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
FDA Guidance Raises Prospect Of More INDs For Supplement Research
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
FDA Guidance Raises Prospect Of More INDs For Supplement Research
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.